iShares U.S. Pharmaceuticals ETF
Price through Oct 6, 2026 · Flows through Oct 5, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Oct 6, 2026. Holdings snapshot retrieved Oct 6, 2026.
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 1M SHOWN · NET −$14M OVER THIS RANGE
Money is leaving — −$14M in net outflows over the past month, about 0.9% of the fund's asset base, while the price has returned +15.9% so far this year. At 0.40% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | LLYELI LILLY | 23.63% | $1157.49 | +1.3% | ||
| 2 | JNJJOHNSON & JOHNSON | 22.28% | $254.78 | +0.7% | ||
| 3 | PFEPFIZER | 4.65% | $27.50 | +0.3% | ||
| 4 | VTRSVIATRIS | 4.60% | $17.54 | -0.5% | ||
| 5 | ZTSZOETIS | 4.42% | $71.33 | -0.1% | ||
| 6 | MRKMERCK & CO | 4.55% | $141.94 | +1.7% | ||
| 7 | RPRXROYALTY PHARMA | 4.38% | $56.44 | -0.4% | ||
| 8 | BMYBRISTOL MYERS SQUIBB | 4.41% | $59.59 | +1.3% | ||
| 9 | JAZZJAZZ PHARMACEUTICALS | 3.48% | $231.39 | -2.0% | ||
| 10 | CORTCORCEPT THERAPEUTICS | 2.52% | $119.57 | -2.0% | ||
| 11 | ELANELANCO ANIMAL HEALTH | 2.52% | $22.48 | -0.1% | ||
| 12 | AXSMAXSOME THERAPEUTICS | 1.82% | $174.34 | -1.5% | ||
| 13 | LGNDLIGAND PHARMACEUTICALS | 1.37% | $296.94 | -3.2% | ||
| 14 | DFTXDefinium Therapeutics | 1.14% | $35.62 | -1.7% | ||
| 15 | INDVINDIVIOR | 0.96% | $35.90 | -0.3% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 38| 1 week | -2.2% |
| 1 month | -6.1% |
| 3 months | -1.9% |
| 6 months | +13.0% |
| YTD | +15.9% |
| 1 year | +30.5% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | −$34M |
| 1 month | −$14M |
| 3 months | +$445M |
| YTD | +$593M |
| 1 year | +$756M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 23.6% of the book; the top ten carry 79%. Spread across 55+ names, it behaves like roughly 8 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| LLY ELI LILLY | $48M | $46M |
| JNJ JOHNSON & JOHNSON | $3M | $4M |
| BMY BRISTOL MYERS SQUIBB | $1M | $5M |
| MRK MERCK & CO | $3M | $2M |
| CORT CORCEPT THERAPEUTICS | $3M | $776,454 |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat IHE on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41B | +$286M | -37bp on fee · 26× the assets · +$286M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.4B | +$199M | -37bp on fee · 12× the assets · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.4B | +$497M | -36bp on fee · 21× the assets · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.3B | +$575M | -36bp on fee · 15× the assets · +$575M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -36bp on fee · 12× the assets · +$412M in over the month | Head-to-head |